Category Archives: News

New Product Launch | DT3C Protein: A Powerful Tool for Validating Antibody Internalization

Are you developing antibody-drug conjugates (ADCs)? Are you seeking a reliable and standardized method to evaluate antibody internalization? We are proud to introduce the DT3C Protein (Cat. No. AME100004) — a novel recombinant fusion protein designed to simulate ADC mechanisms and provide a fast, universal, and functional solution for antibody internalization assessment. 1. What is […]

News 2025-06-13

DIMA Membrane Proteins Empower Nobel Team’s Breakthrough in GPCR Drug Discovery

DIMA’s CXCR4-Nanodisc Empowers New Preprint from David Baker, which is entitled “De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors”

News 2025-05-26

An Invitation|Welcome to meet DIMA BIOTECH in Boston in May

DIMA BIOTECH will showcase over 5,000+ in-stock lead mAbs and 500+ in-stock Nanodisc at 2025 CAS and 2025 PEGS.

News 2025-04-25

Discover DIMA at Membrane Protein Paris 2024

Membrane proteins are essential for cell functions such as maintaining cellular physiological processes, playing crucial roles in substance transport, signal transduction, and cell recognition. They constitute approximately 25% of the total proteome encoded by the human genome. Currently, membrane protein targets account for over 60% of known drug targets and over 90% of antibody drug […]

News 2024-07-26

Connect with DIMA Biotechnology this May at Boston

2024 PEGS Time & Location: May 13-17, 2024, Boston Conference Background: PEGS (Essential Protein & Antibody Engineering Summit) is a premier event in the field of protein engineering and biotherapeutics, featuring comprehensive programming covering all aspects of biologic drug development. DIMA Highlights: At this year’s PEGS Summit, DIMA will present a poster describing the innovative […]

News 2024-05-09

DIMA’s Spotlight on Global Conferences this December

As December unfolds, DIMA, a leading biotechnology company, is gearing up for a strong presence at several esteemed international conferences. This engagement underscores DIMA’s commitment to advancing antibody research and presenting groundbreaking developments in CAR-T therapy.

News 2023-12-11

Recombinant proteins for your cancer research and COVID studies!

News 2022-06-28